TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02610881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid (IFA)
Description: 1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid (IFA)
Description: 1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders (MNP)
Description: One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders (MNP)
Description: One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iron Plus Strategy Counseling
Description: Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iron Plus Strategy Counseling
Description: Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
Study: NCT04269122

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT01620840

Intervention type: DRUG
Intervention: Lacosamide 10mg/ml
Description: intravenous administration up to 10 days
Study: NCT03680144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-MRI (DSC-MRI)
Description: Undergo DSC-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo diagnostic MRI
Study: NCT01185158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839 (IRESSA)
Description: ZD1839: 250mg/day po or via g-tube Q 24 hours
Study: NCT00862563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
Study: NCT04168580

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Intervention
Description: Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
Study: NCT03914105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without music
Description: The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With music
Description: The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration.
Study: NCT01483820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
Study: NCT03682276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody given as an immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a monoclonal antibody given as an immunotherapy
Study: NCT01780350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResQGARD ITD
Description: Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
Study: NCT04599751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair removal treatment
Description: Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
Study: NCT02946424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: 12 month course of daily placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 12 month course of daily simvastatin
Study: NCT02985749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
Study: NCT02582190

Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine group
Description: antiarrhythmic therapy plus colchicine \& antiarrhythmic therapy alone.
Study: NCT00310115

Intervention type: BEHAVIORAL
Intervention: Smoking Prevention Usual Care
Description: Usual care of self-help materials and advice for staying cigarette free
Study: NCT00851760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined surgery
Description: Combined surgery for epiretinal macular membrane and cataract extraction
Study: NCT00310115

Intervention type: BEHAVIORAL
Intervention: Smoking Prevention Usual Care
Description: Usual care of self-help materials and advice for staying cigarette free

Intervention type: BEHAVIORAL
Intervention: Smoking Prevention Usual Care
Description: Usual care of self-help materials and advice for staying cigarette free

Intervention type: BEHAVIORAL
Intervention: Counseling Intervention
Description: 6 x 30 minute counseling sessions over the telephone

Intervention type: BEHAVIORAL
Intervention: Counseling Intervention
Description: 6 x 30 minute counseling sessions over the telephone

Intervention type: BEHAVIORAL
Intervention: Counseling Intervention
Description: 2 in-person counseling sessions
Study: NCT02770690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethyl chloride spray
Description: apply the spray for 5 seconds on the dorsal hand before propofol iv injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: apply lidocaine under the tourniquet state before propofol iv injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: apply normal saline before propofol iv injection
Study: NCT02024048

Intervention type: OTHER
Intervention: OCT
Description: Optical coherence tomography in enhanced depth imaging mode

Intervention type: OTHER
Intervention: OCT
Description: Optical coherence tomography in enhanced depth imaging mode
Study: NCT04852133

Intervention type: OTHER
Intervention: Burn subjects
Description: see eligibility criteria
Study: NCT00325182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Historical controls
Study: NCT00721162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
Study: NCT00585741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-FLT PET
Description: Imaging with 18F-FLT PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-FLT PET
Description: Imaging with 18F-FLT PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-FLT PET
Description: Imaging with 18F-FLT PET
Study: NCT01889940

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training for professionals (Spinal Cord Injury Unit staff).
Description: Prior to the training, separate focus groups for professionals, patients \& families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period.
Study: NCT03203278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based exercise programme
Description: Aerobic, resistance and balance exercises
Study: NCT03387644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin (PG)
Description: Pregabalin 150 mg one hour before the procedure as premedication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo (C)
Description: Placebo tablets one hour before the procedure as premedication.
Study: NCT00814879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg BID

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment regimen
Description: N(t)RTI(s) based backbone plus ritonavir boosted PI
Study: NCT01343225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atripla
Description: once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir ritonavir raltegravir
Description: as directed
Study: NCT00585741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-FLT PET
Description: Imaging with 18F-FLT PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-FLT PET
Description: Imaging with 18F-FLT PET
Study: NCT01753362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00647218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative adjuvant therapy
Description: Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
Study: NCT01195233

Intervention type: DRUG
Group type: OTHER
Intervention: bioxtra
Description: spray /mouth rinse
Study: NCT04633863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial tear MDI - 101
Description: Medical device CE marked - artificial tears containing arabinogalactan, trehalose and hyaluronic acid - 10 weeks treatment
Study: NCT03246503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiliCam estimated bilirubin (BCB)
Description: Images will be obtained using the BiliCam app installed on a commercial smartphone and used to calculated a BCB level. The BCB levels will be used for study purposes only and not used for clinical care
Study: NCT04157335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Description: Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).
Study: NCT00063362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
Study: NCT02694055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Community Case Management
Description: CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Community Case Management
Description: CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
Study: NCT04157335

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).
Study: NCT03385135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300 mg for 4 weeks then 600 mg for 4 weeks in the active group
Study: NCT03795012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
Study: NCT03357380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
Study: NCT05305586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint retained by Bulk-fill flowable
Description: Luxated teeth were splinted with bulk-fill flowable composite

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint retained by Packable Composite
Description: Luxated teeth were splinted with packable composite
Study: NCT02719483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swiss DolorClast
Description: Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional conservative therapy
Description: Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional conservative therapy
Description: Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
Study: NCT02763345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting LIFE electronic Community Case Management
Description: The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study: NCT01905605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphatidylcholine supplementation
Description: phosphatidylcholine concentrate 700 mg twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
Study: NCT02618460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non contrast-enhanced magnetic resonance imaging
Study: NCT00370851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: Intravitreal injection of 125 mg Avastin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Avastin (Bevacizumab)
Description: Intravitreal injection of 125 mg Avastin
Study: NCT04175158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222
Description: Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
Study: NCT04203823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud-based Digital Twin and Meal Prediction algorithms
Description: Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
Study: NCT05063630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical treatment plus intracranial stenting
Description: This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
Study: NCT00647218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic surgical procedure
Description: Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
Study: NCT05063630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment alone
Description: This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
Study: NCT00893776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task Training
Description: Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Training
Description: Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
Study: NCT02694055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removal of point-of-care user fees
Description: User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.